Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Incyte reports robust revenue growth and strategic focus on pediatric market

Incyte's Q4 2022 earnings call showcased strong revenue growth, driven by successful product launches and advancements in the clinical development pipeline.
While facing challenges in market adoption and operational dynamics, Incyte's strategic focus on pediatric patients and engagement with healthcare professionals positions it well for future growth.
Opportunities lie in expanding market reach for Opzelura, exploring new therapeutic applications, and enhancing market penetration efforts through strategic partnerships and product differentiation.
Overall, Incyte's performance reflects a balance of solid financial results, strategic investments in innovation, and a focus on addressing market challenges to drive sustainable growth.

Incyte (INCY) reports robust Q1 growth, eyes international expansion

Incyte's strong Q1 performance driven by Jakafi and Opzelura demand sets the stage for future growth and diversification.
Focusing on high-potential programs and commitment to biologics position Incyte for value creation and market expansion.
Challenges in inventory management and pricing strategies are being addressed as the company eyes multiple launches and international expansion.

Incyte excels in Q2 with strong revenue growth and strategic advancements

Incyte's Q2 2023 performance showcased strong revenue growth driven by key products and successful clinical studies, positioning the company for future success.
The company's focus on innovative therapies and strategic leadership appointments underpin its commitment to advancing in oncology and dermatology.
While facing challenges in revenue guidance and clinical trial progress, Incyte's openness to M&A and growth opportunities signals a proactive approach to driving future expansion.

Incyte reports strong Q3 earnings, focuses on pipeline expansion

Incyte's Q3 earnings reflect robust revenue growth and positive clinical development progress. The company is navigating challenges of patent expiration while focusing on expanding market access and advancing pipeline programs.

Incyte reports robust 2023 earnings, eyes global growth opportunities

Incyte's strong financial performance in 2023 was driven by revenue growth across key products and successful launches like Opzelura.
The company's focus on innovative clinical programs and R&D advancements positions it well for future growth and market expansion.
Challenges in reimbursement, patient retention, and regulatory compliance require strategic planning, while opportunities in global partnerships and market expansion offer avenues for continued success.

Incyte reports strong Q1 growth, eyes oncology opportunities ahead

Incyte delivered solid financial performance in Q1 2024, driven by revenue growth and strong product sales.
The company faces challenges from operational disruptions and competitive landscapes but is well-positioned for growth.
Strategic strengths in pipeline development, financial stability, and market focus position Incyte for future success.
Opportunities in new product launches, market expansion, and capital deployment offer avenues for continued growth.

Incyte reports robust Q2 earnings, raises guidance on key products

Incyte's Q2 2024 performance reflects strong revenue growth, strategic acquisitions, and a focus on high-potential pipeline assets. While facing challenges with rising expenses and pipeline restructuring, the company is well-positioned to capitalize on opportunities in innovative drug development and positive patient outcomes.

Incyte reports robust Q3 earnings, eyes high-impact launches by 2030

Overall, Incyte's Q3 2024 earnings call showcased strong revenue growth, promising product developments, and a focus on expanding its product portfolio and pipeline for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.

Gilead Sciences

Eli Lilly

Eli Lilly and Incyte released positive initial data of their coronavirus treatment when combined with Gilead's remdesivir and said they would seek emergency use authorization from the FDA.
The post Eli Lilly, Incyte Combine Covid Drug With Gilead's, Post Positive Data appeared first on Investor's Business Daily.

Eli Lilly, Incyte Combine Covid Drug With Gilead's, Post Positive Data

Eli Lily & Co. LLY, +1.27% and Incyte Corp. INCY, -0.29% said Monday that their rheumatoid arthritis drug Olumiant helped reduce recovery time in hospitalized COVID-19 patients when it was used in combination with Gilead Sciences Inc.

Shares of Lilly and Incyte gain after late-stage study finds their arthritis drug can help reduce COVID-19 recovery time

Regeneron Pharmaceuticals

Vertex, Inc.

Not all biotechs are created equal.  Strong balance sheets  can separate the weak from the strong.

Biotechs With Strong Balance Sheets

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that Massachusetts General Cancer Center is the recipient of the first Incyte Ingenuity Award, an annual program that was created to support people living with graft-versus-host disease (GVHD) by encouraging innovative and novel solutions that address specific challenges facing the GVHD community.

Incyte Announces Recipient of the Inaugural Incyte Ingenuity Award to Recognize Innovative Solutions that Address Needs in the GVHD Community

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

Incyte (INCY) Down 2.2% Since Last Earnings Report: Can It Rebound?

WILMINGTON, Del.--(BUSINESS WIRE)--Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM

Incyte Announces Pivotal GEOMETRY mono-1 Study Results of Capmatinib (Tabrecta™) in Patients with METex14 Metastatic Non-Small Cell Lung Cancer Published in NEJM

Amgen

Biogen

Vertex Pharmaceuticals

Biotech Industry Near-Term Outlook Modest Amid Coronavirus

Incyte Corporation (INCY) CEO Hervé Hoppenot on Q2 2020 Results - Earnings Call Transcript

Incyte (INCY) easily surpasses earnings and sales expectations in the second quarter as lead drug, Jakafi, reports strong growth.

Incyte (INCY) Beats on Q2 Earnings and Sales on Strong Jakafi

Incyte earnings and revenue rose much more than expected. The biotech reaffirmed guidance.

Incyte Earnings Soar 65%, Easily Beating Views

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #earnings--Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte Reports 2020 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports second-quarter 2020 results.

Is a Beat in the Cards for Incyte's (INCY) Q2 Earnings?

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoint

Incyte Announces REACH3 Trial of Ruxolitinib (Jakafi®) in Patients with Chronic Graft-Versus-Host Disease Met Primary and Both Key Secondary Endpoints

Intuitive Surgical

Lockheed Martin

M/I Homes

Ocular Therapeutix

Cloud Charts Tell Me To Wait Until I See Sunshine

Incyte might finally be convincing Wall Street that its pipeline is the real deal.

Here's Why Incyte Rose 19.1% in the First Half of 2020

BioMarin Pharmaceutical

Lam Research

Seagen

Zoom Video

In a tug of war between bulls and bears, the Dow Jones and S&P 500 gained at least 1% each last week while the Nasdaq Composite Index advanced over 3%.

Nasdaq's Excels in Weekly Performance: 5 Best Stocks in ETF

Incyte (INCY) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Incyte (INCY) Looks Good: Stock Adds 8.3% in Session

Why Is Incyte (INCY) Up 2.9% Since Last Earnings Report?

Morphosys AG - ADR

Incyte (INCY) and partner MorphoSys' application for tafasitamab gets validation by EMA.

Incyte, MorphoSys Application for Lymphoma Drug Validated

We are only in May, but 2020 is already one of the most incredible years in stock market history.

5 Top Health Care Stocks to Buy Now on the Goldman Sachs Conviction List

Incyte Corporation (INCY) CEO Hervé Hoppenot on Q1 2020 Results - Earnings Call Transcript

The biotech's revenue increased solidly in Q1. And it had a very good explanation for its net loss.

Why Incyte's Q1 Loss Isn't As Bad As It Looks

Incyte (INCY) misses on first-quarter earnings due to an upfront payment made in March related to a collaboration agreement. Sales beat on strong Jakafi growth.

Incyte (INCY) Misses Q1 Earnings Estimates, Beats on Revenues

The biotech's revenue soared thanks to the continued success of Jakafi, but its bottom line was weighed down by a licensing deal.

Incyte Reports a Q1 Loss Due to MorphoSys Deal

Incyte (INCY) delivered earnings and revenue surprises of -3675.00% and 4.03%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

News for Incyte Stock (INCY)